Retatrutide Dosing in the Trials: What the Data Actually Showed at 1, 4, 8, and 12 mg

Retatrutide gets talked about like it is a single high-dose story: 12 mg, huge weight loss, next-generation GLP-1. The trial data are more interesting than that.

In the phase 2 obesity trial published in the New England Journal of Medicine, researchers tested once-weekly retatrutide at 1 mg, 4 mg, 8 mg, and 12 mg for 48 weeks. Lilly's later TRIUMPH-1 phase 3 topline tested 4 mg, 9 mg, and 12 mg for 80 weeks, with a 104-week extension in a higher-BMI subgroup. Across both programs, higher doses generally produced greater average weight loss. But the lower and middle doses were not throwaways.

A physician recently argued in a YouTube discussion that 4 mg may be underrated because that is where retatrutide's glucagon-receptor activity starts to matter clinically (video). That is his interpretation, not a PeptidePub dosing recommendation. This article sticks to what the trials reported and why the 4 mg data are worth noticing.

Retatrutide is still investigational and is not FDA-approved. Dosing decisions belong with a qualified clinician. PeptidePub's lane is education, vendor transparency, and price comparison. We do not tell readers what dose to take.

What makes retatrutide a triple agonist?

Retatrutide activates three hormone receptor systems: GLP-1, GIP, and glucagon.

GLP-1 is the familiar target behind semaglutide. It is associated with appetite reduction, slower gastric emptying, and glucose effects. GIP is the second incretin target also used by tirzepatide. Retatrutide adds glucagon-receptor agonism, which is the third target that makes it a triple agonist.

The glucagon piece is the part people argue about. In normal physiology, glucagon is often described as the hormone that raises blood sugar. But glucagon signaling also intersects with appetite, lipolysis, fatty-acid oxidation, energy expenditure, and liver-fat biology. That is why triple-agonist drug development is interested in it.

A plain-English way to think about receptor activation is the EC50 concept. A receptor target does not simply flip from off to on. As drug exposure rises, receptor activation rises along a curve. The EC50 is the concentration where a drug produces about half of its maximal effect at that receptor in a lab system. If one receptor needs more exposure than another, lower doses may mostly express the easier-to-activate effects, while higher doses may bring more of the harder-to-activate target into play.

The important caveat: lab potency does not translate cleanly into a consumer dose rule. The clinical question is not "what dose activates glucagon?" in isolation. It is what happened to weight, metabolic markers, and tolerability in actual randomized trials.

Phase 2: what 1, 4, 8, and 12 mg reported

The NEJM phase 2 obesity trial randomized 338 adults with obesity, or overweight plus a weight-related condition, to placebo or once-weekly retatrutide. The trial included 1 mg, two 4 mg arms, two 8 mg arms, and a 12 mg arm. Some arms started lower and escalated, which matters because tolerability differed by starting dose.

At 24 weeks, the trial reported least-squares mean weight changes of:

• 1 mg: -7.2%
• Combined 4 mg: -12.9%
• Combined 8 mg: -17.3%
• 12 mg: -17.5%
• Placebo: -1.6%

At 48 weeks, the trial reported:

• 1 mg: -8.7%
• Combined 4 mg: -17.1%
• Combined 8 mg: -22.8%
• 12 mg: -24.2%
• Placebo: -2.1%

That is the core dose-response story. The 12 mg arm was strongest at 48 weeks. The 8 mg arm was close behind. But the 4 mg arm still reported an average 17.1% weight reduction at 48 weeks, which is substantial in any obesity trial context.

The responder data tell the same story. At 48 weeks, the phase 2 trial reported that at least 15% weight loss occurred in 60% of participants on 4 mg, 75% on 8 mg, 83% on 12 mg, and 2% on placebo. Again: higher dose, stronger effect, but 4 mg was not a minor-response arm.

Why the 4 mg question is defensible

The cleanest version of the 4 mg argument is not "4 mg is best" or "4 mg is enough." Those would be dosing claims, and the trials were not designed to tell any individual what to use.

The defensible point is narrower: 4 mg was the lowest phase 2 dose with a large jump from 1 mg in mean weight loss, and in TRIUMPH-1 it remained clinically meaningful over a much longer 80-week phase 3 trial.

In phase 2, moving from 1 mg to 4 mg changed the 48-week average from -8.7% to -17.1%. Moving from 4 mg to 8 mg changed it from -17.1% to -22.8%. Moving from 8 mg to 12 mg changed it from -22.8% to -24.2%. That does not prove a mechanistic threshold, but it does show why people are paying attention to the 4 mg step.

The physician's glucagon interpretation fits one plausible explanation: at higher exposure, retatrutide may express more of its third receptor target. The published mechanism literature supports retatrutide as a GIP, GLP-1, and glucagon receptor agonist, and the MASLD substudy notes that retatrutide is less potent than endogenous ligands at human glucagon and GLP-1 receptors while more potent at GIP receptors. But the trial itself reported outcomes, not a per-patient receptor-activation meter.

So the honest phrasing is: 4 mg is where the clinical curve starts getting interesting, and one physician has interpreted that as the point where glucagon activity may become more meaningful. The data support the first clause more strongly than the second.

Tolerability: why dose range matters

The high-dose headline comes with a tolerability tradeoff.

In the phase 2 NEJM trial, gastrointestinal adverse events were the most common. They were dose-related, mostly mild to moderate, and partly mitigated by starting at 2 mg rather than 4 mg. Adverse events leading to discontinuation were reported in 0% of placebo participants, 6% and 9% in the two 4 mg arms, 14% and 6% in the two 8 mg arms, and 16% in the 12 mg arm.

The skin-sensation signal also deserves careful wording. The phase 2 paper did not report the exact YouTube-style claim that dysesthesia was about 8% at 4 mg. In NEJM Table 3, the related category was "hyperesthesia or related adverse event." It was reported in 1% of placebo participants, 6% in each 4 mg arm, 3% and 14% in the two 8 mg arms, and 13% in the 12 mg arm. The supplement lists the related preferred terms, including hyperesthesia, sensitive skin, allodynia, skin burning sensation, and paresthesia.

That distinction matters. If a number is not in the paper under the same event term and dose group, it should not be repeated as if it were.

Heart rate is another example. The phase 2 paper reported dose-dependent increases that peaked at 24 weeks and declined afterward. The supplement's heart-rate figure shows week-24 increases up to about 6.7 beats per minute in the displayed treatment groups. That is a trial observation, not a prediction for an individual.

Phase 3 TRIUMPH-1: longer trial, same broad pattern

Lilly's May 2026 TRIUMPH-1 topline gives more context, though it is still a company press release rather than a peer-reviewed publication.

In the phase 3 obesity master trial, Lilly reported 80-week average weight changes of -19.0% at 4 mg, -25.9% at 9 mg, -28.3% at 12 mg, and -2.2% with placebo. The 12 mg arm also had 45.3% of participants achieve at least 30% weight loss at 80 weeks. In a prespecified extension among participants with baseline BMI of at least 35 who completed the main study and tolerated assigned medication, Lilly reported up to -30.3% average weight loss at 104 weeks in the 12 mg-to-maximum-tolerated-dose path.

TRIUMPH-1 also reported tolerability by dose. Discontinuations due to adverse events were 4.1% at 4 mg, 6.9% at 9 mg, 11.3% at 12 mg, and 4.9% with placebo. Dysesthesia was reported in 5.1%, 12.3%, and 12.5% of participants at 4, 9, and 12 mg, respectively, versus 0.9% with placebo.

That makes the phase 3 picture more nuanced than "go straight to the top." The highest dose had the largest average effect. The 4 mg dose still reported nearly 20% average weight loss at 80 weeks, with lower observed adverse-event discontinuation than 12 mg in the topline release.

The practical takeaway for researchers

If you are researching retatrutide, the trial dose range is worth understanding before you assume the only meaningful number is 12 mg.

The phase 2 data showed a large efficacy step from 1 mg to 4 mg, further gains at 8 mg, and the highest mean loss at 12 mg. The phase 3 topline showed the same basic direction over 80 weeks: 4 mg was meaningful, 9 mg was stronger, 12 mg was strongest. Tolerability generally moved in the other direction, especially for GI events and adverse-event discontinuations.

That is not a recommendation to choose any dose. It is a reminder to read the actual trial arms. Retatrutide's appeal is not just that the top dose produced a large number. It is that the entire studied range produced a visible dose-response curve, and the 4 mg arm sits at an interesting point on that curve.

Where PeptidePub fits

Whatever protocol someone is already researching with a qualified clinician, cost per milligram can vary a lot by vendor. That is where PeptidePub is useful.

Compare current retatrutide vendor pricing on the retatrutide price page.

If someone already has their own protocol and needs to check concentration math, the reconstitution calculator follows the same principle as this article: your number, from your own protocol. No dose suggestions.

Sources checked

• Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526. DOI: 10.1056/NEJMoa2301972. PMID: 37366315.
• NEJM supplementary appendix for the same phase 2 trial, including participant disposition, heart-rate figure, and hyperesthesia-related adverse-event details.
• Eli Lilly investor release, May 21, 2026: TRIUMPH-1 topline retatrutide phase 3 obesity results.
• Nature Medicine 2024 MASLD substudy of the phase 2 trial, including mechanism context and liver-fat findings.
• YouTube physician discussion used only as interpretation context: https://www.youtube.com/watch?v=oUL18iO18Oc.